DB05172ExperimentalSmall molecule
AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.
- Mechanism
- Curator reviewed
AT3022 utilizes the Company’s proprietary PassPort™ Transdermal System, developed to deliver watersoluble small molecules, proteins, carbohydrates and oligonucleotides across the skin. AT3022 is designed to provide a safer and more efficacious alternative to the currently marketed fentanyl patches that can only deliver the highly lipid-soluble base form of fentanyl.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic).Curator reviewed
- Code names
- AT3022
Which companies are running trials of AT3022, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account